NEW YORK, May 9, 2014 /PRNewswire/ -- Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of Chelsea Therapeutics International, Ltd. ("Chelsea" or the "Company") (NASDAQ: CHTP) concerning the proposed acquisition of the Company by H. Lundbeck ("Lundbeck").
Under the terms of the transaction, Lundbeck will acquire Chelsea for approximately $658 million. Chelsea shareholders will receive $6.44 in cash per share and contingent value rights that could pay up to $1.50.
Our investigation concerns whether the Chelsea board of directors is fulfilling its fiduciary duties, maximizing the value of the Company, disclosing all material benefits and costs, and obtaining full and fair consideration for Company shareholders.
If you own Chelsea shares and wish to discuss this matter with us, or have any questions concerning your rights and interests with regard to this matter, please contact:
Benjamin I. Sachs-Michaels, Esq.
Robert I. Harwood, Esq.
Harwood Feffer LLP
488 Madison Avenue
New York, New York 10022
Phone Numbers: (877) 935-7400
(212)935-7400
Email: bsachsmichaels@hfesq.com
Website: http://www.hfesq.com
Harwood Feffer has been representing individual and institutional investors for many years, serving as lead counsel in numerous cases in federal and state courts. Please visit the Harwood Feffer LLP website (http://www.hfesq.com) for more information about the firm.
Attorney Advertising © 2014 Harwood Feffer LLP. The law firm responsible for this advertisement is Harwood Feffer LLP (www.hfesq.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Logo - http://photos.prnewswire.com/prnh/20120215/MM54604LOGO
SOURCE Harwood Feffer LLP
